论文部分内容阅读
目的:探讨阿托伐他汀联合氯吡格雷治疗急性脑梗死的临床疗效和预后。方法:120例急性脑梗死患者,随机分为阿托伐他汀联合氯吡格雷治疗组(60例)和单用氯吡格雷治疗组(60例),随访6个月,比较2组治疗前、后的美国国立卫生研究院卒中量表(NIHSS)评分、日常生活能力指数(BI)、改良的Rankin(mRS)评分和简易智能量表(MMSE)评分。结果:2组患者在治疗后3个月和6个月的NIHSS、BI和mRS评分均比治疗前有好转,差异均有显著性(P<0.05)。阿托伐他汀联合氯吡格雷治疗组在治疗后6个月时NIHSS、BI和mRS评分的好转优于单用氯吡格雷治疗组,且差异有显著性(P<0.05)。MMSE的变化无统计学意义。结论:阿托伐他汀联合氯吡格雷治疗有利于神经功能、日常生活能力的恢复,改善预后,可作为急性脑梗死治疗的联合药物。
Objective: To investigate the clinical efficacy and prognosis of atorvastatin combined with clopidogrel in the treatment of acute cerebral infarction. Methods: One hundred and twenty patients with acute cerebral infarction were randomly divided into two groups: atorvastatin combined with clopidogrel (60 cases) and clopidogrel alone (60 cases), followed up for 6 months. Before and after treatment, NIH Stroke Scale (NIHSS) score, daily living ability index (BI), modified Rankin (mRS) score, and MMSE score. Results: The scores of NIHSS, BI and mRS in both groups at 3 months and 6 months after treatment were better than those before treatment, the difference was significant (P <0.05). The improvement of NIHSS, BI and mRS scores at 6 months after treatment in atorvastatin plus clopidogrel group was better than that in clopidogrel alone group, and the difference was significant (P <0.05). MMSE changes were not statistically significant. Conclusion: Atorvastatin combined with clopidogrel is beneficial to the recovery of neurological function, daily living ability and prognosis, which can be used as a combination therapy for acute cerebral infarction.